Full text is available at the source.
Abstract
GLP-1 receptor agonists could significantly reshape obesity management but may also reinforce existing health inequities.
- Growing reliance on GLP-1 therapies may lead to a treatment-driven model of obesity management that is costly and difficult to sustain.
- Gaps in system connections and dominant mental models can affect the integration of GLP-1 therapies into obesity care.
- Unintended consequences related to GLP-1 therapy use have been identified, highlighting the need for a systems-based approach.
- Dietitians are positioned to play a vital role in obesity care but face structural barriers that limit their effectiveness.
- System-level changes are necessary to fully leverage dietitians' expertise and promote equitable obesity care.
Simplified